Lomond Therapeutics
lomondther.com
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
US FDA clears Lomond Therapeutics' IND application for phase 1 multicenter study of lonitoclax in patients with relapsed/refractory AML
US FDA clears Lomond Therapeutics' IND application for phase 1 multicenter study of lonitoclax in patients with relapsed/refractory AML
Read more
Report
Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, today announ
Read more
Report
LOMOND THERAPEUTICS REPORTS RESULTS FROM ONGOING CLINICAL STUDIES OF LONITOCLAX, A SELECTIVE BCL-2 INHIBITOR WITH BEST-IN-CLASS SELECTIVITY VERSUS BCL-XL AND NO CYP 3A4 LIABILITY
Lomond Therapeutics, a spin-out of Eilean Therapeutics LLC, a precision oncology-focused discovery and development platform, today announced results from single ascending dose Phase 1 clinical studies of oral once-daily lonitoclax. In this series of healt
Read more
Report
LOMOND THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1 STUDY OF LONITOCLAX, A SELECTIVE BCL2 INHIBITOR, FOR CHRONIC LYMPHOCYTIC ...
Read more
Report
Lomond Therapeutics divulges MAP4K1 inhibitors
Lomond Therapeutics Inc. has prepared and tested compounds having N-arylpyrimidin-2-amine derivatives and acting as protein kinase inhibitors, particularly mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1). As such, they are r
Read more
Report